SNX-5422 is under clinical development by Esanex and currently in Phase I for Solid Tumor. According to GlobalData, Phase I drugs for Solid Tumor have a 54% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how SNX-5422’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

SNX-5422 overview

SNX-5422 (PF-4929113) is under development for the treatment of patients with solid tumors, prostate cancer, lung adenocarcinoma, blood cancer (refractory hematological malignancies) including non-hodgkin's lymphoma, and pancreatic tumor, thyroid cancer, small-cell lung cancer, non-small cell lung cancer. SNX-5422 is administered through oral route in the form of capsule. It is a bioavailable mesylate salt of a synthetic prodrug that acts by targeting human heat-shock protein 90 (Hsp90). The drug candidate was also under development for lymphoma and non-Hodgkin lymphoma and HER2 positive cancers (metastatic breast cancer, non-small cell lung cancer, urothelial cancer, gastrointestinal tumor and gastroesophageal carcinomas) and chronic lymphocytic leukemia, metastatic renal cell carcinoma and neuroendocrine tumors.

For a complete picture of SNX-5422’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.